"Folate supplementation with either folic or folinic acid decreases the plasma homocysteine level and consequently protects against potential cardiovascular risks."
Sunset, LA (PRWEB) October 21, 2014
Over one million people in the U.S. suffer from rheumatoid arthritis (RA), an autoimmune disease marked by pain, swelling, and stiffness in the joints. The most common first line treatment for RA is methotrexate, a prescription medication belonging to the class of drugs knows as DMARDS. Though helpful in managing autoimmune disorders such as RA, Psoriasis, and Chron's, methotrexate depletes folate levels and causes a dangerous rise in the amino acid homocysteine, which has been linked to cardiovascular disease and stroke.
According to Rheumatology.Org, "Research shows that people with RA, mainly those whose disease is not well controlled, have a higher risk for heart disease and stroke." In addition, common adverse effects that are thought to be caused by these low folate levels cause many patients to discontinue methotrexate treatment-these range from mild, such as mouth ulcers, to severe, such as methotrexate toxicity. A 2014 bulletin released by Edmund Senior Health Clinic found that individuals who take methotrexate for rheumatoid arthritis can safely use folate supplements, which decreased the usual side effects that can cause patients to stop treatment altogether.
Adding folic acid or folinic acid to RA treatment to address these issues is recommended by leading authorities. A study published in Rheumatology (Volume 41, Issue 6) concluded: " Low dose methotrexate treatment in RA patients leads to an increased plasma homocysteine level. Concomitant folate supplementation with either folic or folinic acid decreases the plasma homocysteine level and consequently protects against potential cardiovascular risks." http://www.ncbi.nlm.nih.gov/pubmed/12048292. Furthermore, a review published in Rheumatology (2004, 43: 267-271) found supplementation of methotrexate with folate to offset the high homocysteine associated with its use, improve treatment tolerability, and lower cardiovascular risk in RA patients. http://rheumatology.oxfordjournals.org/content/41/6/658.full
EnLyte is an advanced generation folate therapy that, based on these recommendations, is an ideal complement to methotrexate treatment to combat its associated serious folate deficiency. EnLyte contains both recommended forms-folic acid and folinic acid-plus the most reduced form- L-Methylfolate magnesium-a reduced form necessary to address common genetic enzyme defects such as MTHFR, carried by as much as 80% of the US population. EnLyte also contains b vitamin metabolites critical to lowering homocysteine- b1, b2, b3, b6, b12, betaine-plus zinc, magnesium, and vitamin c. EnLyte is FDA regulated and carries the FDA USP for Dissolution of Folates-a distinction carried by very few folate products. Because EnLyte is dosed once a day, covered by most insurance plans, Tricare, many state Medicaid plans, and does not carry the side effect and drug interactions found in other options, it is the perfect addition to methotrexate treatment for patients with autoimmune disorders.
For samples of EnLyte or to learn more call 985-788-7755.